Abbisko Cayman Limited (HK:2256) has released an update.
Stay Ahead of the Market:
- Discover outperforming stocks and invest smarter with Top Smart Score Stocks
- Filter, analyze, and streamline your search for investment opportunities using Tipranks' Stock Screener
Abbisko Cayman Limited’s subsidiary, Abbisko Therapeutics, has received approval from China’s Center for Drug Evaluation to begin a critical clinical study for irpagratinib, a promising new treatment for advanced hepatocellular carcinoma. This study aims to establish irpagratinib’s efficacy, potentially making it the first FGFR4 inhibitor available for patients with FGF19 overexpression, a condition that affects about 30% of HCC patients worldwide. Such advancements could herald a pivotal shift in treatment options for this challenging cancer type.
For further insights into HK:2256 stock, check out TipRanks’ Stock Analysis page.